{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:16:00Z","timestamp":1778685360475,"version":"3.51.4"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":550,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["INDO\/FRC\/452\/S-11\/2019-20-lHD"],"award-info":[{"award-number":["INDO\/FRC\/452\/S-11\/2019-20-lHD"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/RLF\/RE-ENTRY\/06\/2010"],"award-info":[{"award-number":["BT\/RLF\/RE-ENTRY\/06\/2010"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR13023\/MED\/31\/311\/2015"],"award-info":[{"award-number":["BT\/PR13023\/MED\/31\/311\/2015"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SB\/SO\/HS-053\/2013"],"award-info":[{"award-number":["SB\/SO\/HS-053\/2013"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012323","name":"CSIR-Indian Institute of Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["HCP-23"],"award-info":[{"award-number":["HCP-23"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["HCP-0008"],"award-info":[{"award-number":["HCP-0008"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["P07\/MLP-AS\/578"],"award-info":[{"award-number":["P07\/MLP-AS\/578"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.exphem.2023.05.005","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T20:40:30Z","timestamp":1684960830000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Unifying targeted therapy for leukemia in the era of PARP inhibition"],"prefix":"10.1016","volume":"124","author":[{"given":"Liberalis Debraj","family":"Boila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-1774","authenticated-orcid":false,"given":"Amitava","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2023.05.005_bib0001","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2023.05.005_bib0002","doi-asserted-by":"crossref","first-page":"13576","DOI":"10.1073\/pnas.1301891110","article-title":"Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation","volume":"110","author":"Miraki-Moud","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2023.05.005_bib0003","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tig.2014.06.003","article-title":"Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches","volume":"30","author":"Dietlein","year":"2014","journal-title":"Trends Genet"},{"key":"10.1016\/j.exphem.2023.05.005_bib0004","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1126\/science.1156906","article-title":"ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis","volume":"320","author":"Ishikawa","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.exphem.2023.05.005_bib0005","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","article-title":"Exploiting DNA replication stress for cancer treatment","volume":"79","author":"Ubhi","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0006","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2023.05.005_bib0007","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2023.05.005_bib0008","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2023.05.005_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2023.05.005_bib0010","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1073\/pnas.1012363108","article-title":"Role for topoisomerase 1 in transcription-associated mutagenesis in yeast","volume":"108","author":"Lippert","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2023.05.005_bib0011","doi-asserted-by":"crossref","first-page":"13902","DOI":"10.1038\/s41598-018-32308-2","article-title":"Oxidative DNA damage induced by ROS-modulating agents with the ability to target DNA: a comparison of the biological characteristics of citrus pectin and apple pectin","volume":"8","author":"Salehi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.exphem.2023.05.005_bib0012","doi-asserted-by":"crossref","first-page":"19881","DOI":"10.1074\/jbc.M114.571588","article-title":"Nucleosomes suppress the formation of double-strand DNA breaks during attempted base excision repair of clustered oxidative damages","volume":"289","author":"Cannan","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2023.05.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016428","article-title":"Sources of DNA double-strand breaks and models of recombinational DNA repair","volume":"6","author":"Mehta","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0014","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2023.05.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","author":"Scharer","year":"2013","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-genet-112414-054722","article-title":"Eukaryotic mismatch repair in relation to DNA replication","volume":"49","author":"Kunkel","year":"2015","journal-title":"Ann Rev Genet"},{"key":"10.1016\/j.exphem.2023.05.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012740","article-title":"Repair of strand breaks by homologous recombination","volume":"5","author":"Jasin","year":"2013","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0019","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Marechal","year":"2013","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0020","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019101801","article-title":"DNA damage kinase signaling: checkpoint and repair at 30 years","volume":"38","author":"Lanz","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2023.05.005_bib0021","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.3390\/ijms22084134","article-title":"The multifaceted roles of Ku70\/80","volume":"22","author":"Zahid","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2023.05.005_bib0022","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.3390\/cancers14163888","article-title":"BRCA mutations in ovarian and prostate cancer: bench to bedside","volume":"14","author":"Boussios","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2023.05.005_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.11.024","article-title":"UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors","volume":"176","author":"Jachimowicz","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2023.05.005_bib0024","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj3420249","article-title":"Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions","volume":"342","author":"D'Amours","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2023.05.005_bib0025","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1093\/nar\/gkn771","article-title":"Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes","volume":"36","author":"Gagne","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0026","doi-asserted-by":"crossref","first-page":"22090","DOI":"10.1073\/pnas.1009182107","article-title":"Apurinic\/apyrimidinic (AP) site recognition by the 5\u2032-dRP\/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1)","volume":"107","author":"Khodyreva","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2023.05.005_bib0027","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1021\/bi00189a012","article-title":"Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage","volume":"33","author":"Satoh","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.exphem.2023.05.005_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.793884","article-title":"Immediate-early, early, and late responses to DNA double stranded breaks","volume":"13","author":"Kieffer","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.exphem.2023.05.005_bib0029","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/emboj.2009.206","article-title":"PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination","volume":"28","author":"Bryant","year":"2009","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2023.05.005_bib0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0031","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0032","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1093\/nar\/gkq1241","article-title":"ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate","volume":"39","author":"Strom","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0033","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0034","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15252\/embj.201693860","article-title":"Interplay between Fanconi anemia and homologous recombination pathways in genome integrity","volume":"35","author":"Michl","year":"2016","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2023.05.005_bib0035","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1038\/s41467-020-17537-2","article-title":"Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers","volume":"11","author":"Glodzik","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2023.05.005_bib0036","doi-asserted-by":"crossref","first-page":"22609","DOI":"10.1073\/pnas.1903765116","article-title":"DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation","volume":"116","author":"Abbotts","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2023.05.005_bib0037","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-14-0201","article-title":"TGF\u03b2 induces \u201cBRCAness\u201d and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes","volume":"12","author":"Liu","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0038","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced ermline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2023.05.005_bib0039","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","article-title":"Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial","volume":"20","author":"Konstantinopoulos","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0040","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0041","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0042","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","article-title":"FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer","volume":"23","author":"Balasubramaniam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0043","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0044","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0045","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0046","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0047","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0048","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0049","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0050","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0051","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Network","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0052","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2023.05.005_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221288","article-title":"Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia","volume":"14","author":"Pouliot","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2023.05.005_bib0054","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2016.11.021","article-title":"Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells","volume":"386","author":"Piao","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2023.05.005_bib0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41375-020-0864-3","article-title":"TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition","volume":"35","author":"Bamezai","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.05.005_bib0056","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.05.005_bib0057","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41467-017-00210-6","article-title":"Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia","volume":"8","author":"Knittel","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2023.05.005_bib0058","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.leukres.2013.12.019","article-title":"Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro","volume":"38","author":"Dilley","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0059","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.05.005_bib0060","doi-asserted-by":"crossref","first-page":"43978","DOI":"10.18632\/oncotarget.6287","article-title":"PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia","volume":"6","author":"Herriott","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2023.05.005_bib0061","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.05.005_bib0062","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3390\/ijms21041177","article-title":"DNA damage and DNA damage response in chronic myeloid leukemia","volume":"21","author":"Popp","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2023.05.005_bib0063","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/onc.2012.203","article-title":"Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias","volume":"32","author":"Tobin","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2023.05.005_bib0064","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3324\/haematol.2008.001933","article-title":"Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes","volume":"94","author":"Gaymes","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2023.05.005_bib0065","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1158\/1078-0432.CCR-05-1224","article-title":"The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks","volume":"11","author":"Smith","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0066","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.3993","article-title":"Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors","volume":"21","author":"Esposito","year":"2015","journal-title":"Nature medicine"},{"key":"10.1016\/j.exphem.2023.05.005_bib0067","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1172\/JCI17595","article-title":"Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair","volume":"112","author":"Alcalay","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2023.05.005_bib0068","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2012.079251","article-title":"Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies","volume":"98","author":"Gaymes","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2023.05.005_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.989483","article-title":"The genetics of myelodysplastic syndromes and the opportunities for tailored treatments","volume":"12","author":"Kontandreopoulou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0070","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2023.05.005_bib0071","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/s41375-022-01536-x","article-title":"In vivo anti-tumor effect of PARP inhibition in IDH1\/2 mutant MDS\/AML resistant to targeted inhibitors of mutant IDH1\/2","volume":"36","author":"Gbyli","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.05.005_bib0072","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1\/2-mutant inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0073","doi-asserted-by":"crossref","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0074","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1158\/0008-5472.CAN-20-3761","article-title":"TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors","volume":"81","author":"Maifrede","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2023.05.005_bib0076","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41375-023-01833-z","article-title":"KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition","volume":"37","author":"Boila","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.05.005_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0078","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2018-02-834895","article-title":"Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors","volume":"132","author":"Maifrede","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.05.005_bib0079","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.celrep.2018.08.002","article-title":"PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes","volume":"24","author":"Hamard","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2023.05.005_bib0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-rearranged leukemias-an update on science and clinical approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front Pediatr"},{"key":"10.1016\/j.exphem.2023.05.005_bib0081","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature13483","article-title":"DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier","volume":"514","author":"Santos","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2023.05.005_bib0082","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/bloodadvances.2017006247","article-title":"MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs","volume":"1","author":"Maifrede","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2023.05.005_bib0083","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.278.5340.1059","article-title":"Oncogenic transcription factors in the human acute leukemias","volume":"278","author":"Look","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.exphem.2023.05.005_bib0084","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/leu.2015.133","article-title":"The leukemia-associated RUNX1\/ETO oncoprotein confers a mutator phenotype","volume":"30","author":"Forster","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.05.005_bib0085","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/cancers11101591","article-title":"Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies","volume":"11","author":"Noguera","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.exphem.2023.05.005_bib0086","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1172\/JCI90825","article-title":"Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells","volume":"127","author":"Nieborowska-Skorska","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2023.05.005_bib0087","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/proteomes10020016","article-title":"Applications of proteomics in ovarian cancer: dawn of a new era","volume":"10","author":"Ghose","year":"2022","journal-title":"Proteomes"},{"key":"10.1016\/j.exphem.2023.05.005_bib0088","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2023.05.005_bib0089","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clbc.2017.12.010","article-title":"BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy","volume":"18","author":"Gornstein","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.exphem.2023.05.005_bib0090","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2016.71.3677","article-title":"Somatic BRCA1\/2 recovery as a resistance mechanism after exceptional response to poly (ADP-ribose) polymerase inhibition","volume":"35","author":"Lheureux","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0091","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2023.05.005_bib0092","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2017.40","article-title":"BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","volume":"116","author":"Pishvaian","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2023.05.005_bib0093","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0094","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2023.05.005_bib0095","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2023.05.005_bib0096","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2023.05.005_bib0097","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/bloodadvances.2019000756","article-title":"Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor","volume":"3","author":"Nieborowska-Skorska","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2023.05.005_bib0098","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/leu.2014.179","article-title":"Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1\/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors","volume":"29","author":"Wichmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.05.005_bib0099","doi-asserted-by":"crossref","first-page":"12628","DOI":"10.3390\/ijms222312628","article-title":"BRCA mutations in prostate cancer: assessment, implications and treatment considerations","volume":"22","author":"Shah","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2023.05.005_bib0100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0101","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0102","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0103","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.exphem.2023.05.005_bib0104","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2023.05.005_bib0105","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/2159-8290.CD-13-0230","article-title":"Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition","volume":"4","author":"Gonzalez-Billalabeitia","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2023.05.005_bib0106","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ygyno.2016.07.092","article-title":"Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes","volume":"142","author":"Wang","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0107","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.05.005_bib0108","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphar.2020.00170","article-title":"Poly(ADP-ribose)polymerase (PARP) inhibitors and radiation therapy","volume":"11","author":"Jannetti","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0109","doi-asserted-by":"crossref","first-page":"e60408","DOI":"10.1371\/journal.pone.0060408","article-title":"PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells","volume":"8","author":"Chatterjee","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2023.05.005_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-016-2275-x","article-title":"Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study","volume":"131","author":"Chabot","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1101\/gad.184341.111","article-title":"Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains","volume":"26","author":"Trowbridge","year":"2012","journal-title":"Genes Develop"},{"key":"10.1016\/j.exphem.2023.05.005_bib0112","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/ph14070641","article-title":"Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia","volume":"14","author":"Sorrentino","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.exphem.2023.05.005_bib0113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.onc.1208005","article-title":"Modulation of DNMT1 activity by ADP-ribose polymers","volume":"24","author":"Reale","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2023.05.005_bib0114","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","article-title":"Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents\u2014a potential therapy for cancer","volume":"30","author":"Muvarak","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2023.05.005_bib0115","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","article-title":"An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations","volume":"24","author":"Pulliam","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0116","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","article-title":"Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia","volume":"28","author":"Baer","year":"2022","journal-title":"Clinical Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0117","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1084\/jem.20180139","article-title":"The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer","volume":"215","author":"Li","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2023.05.005_bib0118","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1038\/s41467-021-25432-7","article-title":"Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity","volume":"12","author":"Cindy Yang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2023.05.005_bib0119","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.3390\/ijerph19148577","article-title":"Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer","volume":"19","author":"Revythis","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.exphem.2023.05.005_bib0120","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s40425-019-0619-8","article-title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","volume":"7","author":"Vidotto","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.exphem.2023.05.005_bib0121","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2023.05.005_bib0122","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2023.05.005_bib0123","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0124","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2023.05.005_bib0125","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2023.05.005_bib0126","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.celrep.2018.05.034","article-title":"Simultaneous targeting of PARP1 and RAD52 triggers dual synthetic lethality in BRCA-deficient tumor cells","volume":"23","author":"Sullivan-Reed","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2023.05.005_bib0127","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108221","article-title":"TGFbetaR-SMAD3 signaling induces resistance to PARP ihibitors in the bone marrow microenvironment","volume":"33","author":"Le","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2023.05.005_bib0128","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2023.05.005_bib0129","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","article-title":"A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia","volume":"23","author":"Gojo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.05.005_bib0130","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","article-title":"A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia","volume":"23","author":"Pratz","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2300228X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2300228X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:34:26Z","timestamp":1778682866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X2300228X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":130,"alternative-id":["S0301472X2300228X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2023.05.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unifying targeted therapy for leukemia in the era of PARP inhibition","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2023.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}